How were Oncorus' earnings last quarter?

Oncorus, Inc. (NASDAQ:ONCR) announced its earnings results on Monday, May, 22nd. The company reported ($1.18) earnings per share for the quarter, missing the consensus estimate of ($0.70) by $0.48.

What other stocks do shareholders of Oncorus own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Oncorus investors own include Cronos Group (CRON) , Deere & Company (DE) , GrowGeneration (GRWG) , Immunomedics (IMMU) , Teck Resources (TECK) , Abbott Laboratories (ABT) , Ability (ABIL) , AbbVie (ABBV) , Atlas Air Worldwide (AAWW) .

When did Oncorus IPO?

Oncorus (ONCR) raised $87 million in an IPO on Friday, October 2nd 2020. The company issued 5,800,000 shares at $14.00-$16.00 per share. Jefferies, Evercore ISI and Piper Sandler acted as the underwriters for the IPO.

NASDAQ:ONCR

Oncorus (ONCR) Stock Price, News & Analysis

→ New crypto project uncovers 2,050% in 65 days (From InvestorPlace) (Ad)

Free ONCR Stock Alerts

Notice: This company has been marked as potentially delisted and may not be actively trading.

Compare

Today's Range: $0.13
▼
$0.20
50-Day Range: $0.01
▼
$0.13
52-Week Range: $0.01
▼
$0.47

Volume: 135,900 shs
Average Volume: 1.33 million shs
Market Capitalization: $3.29 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: N/A

Stock Analysis Earnings Headlines Insider Trades Ownership Social Media

Get Oncorus alerts:

Ad InvestorPlace

New crypto project uncovers 2,050% in 65 days

During the event on Tuesday, April 23 at 10 am ET, I’ll be giving away the name and ticker symbol of crypto that could surge in price. I believe it will be the best performing crypto of 2024.

Just click here to sign up and be among the first to get it.

About Oncorus Stock (NASDAQ:ONCR)

Oncorus, Inc., a clinical-stage biopharmaceutical company, focuses on developing viral immunotherapies for cancer patients. The company develops ONCR-021 for the treatment of non-small cell lung cancer, renal cell carcinoma, melanoma, and anaplastic thyroid cancer; and ONCR-788 for the treatment of small cell lung cancer, neuroendocrine prostate, and other neuroendocrine cancers. Oncorus, Inc. was incorporated in 2015 and is headquartered in Andover, Massachusetts.

Ad InvestorPlace

New crypto project uncovers 2,050% in 65 days

During the event on Tuesday, April 23 at 10 am ET, I’ll be giving away the name and ticker symbol of crypto that could surge in price. I believe it will be the best performing crypto of 2024.

Just click here to sign up and be among the first to get it.

ONCR Stock News Headlines

February 26, 2024 | benzinga.com

Oncorus Inc rdinary Shares Stock (OTC:ONCR) Dividends: History, Yield and Dates

December 29, 2023 | uk.finance.yahoo.com

Oncorus, Inc. (ONCR) stock price, news, quote & history – Yahoo Finance

April 19, 2024 | Altimetry (Ad)

I’m officially sounding the alarm.

AI has been the hottest financial story of 2023. And rightly so – AI stocks have beat the broader market by over 62%. But right now, my system is warning me that many AI stocks are riding higher on hype alone.

December 18, 2023 | investing.com

Comera Life Sciences Holdings Inc

October 28, 2023 | morningstar.com

Oncorus Inc Ordinary Shares

October 16, 2023 | investing.com

ONCR Historical Data

June 16, 2023 | msn.com

What's Going On With Oncorus (ONCR) Stock Friday?

June 2, 2023 | msn.com

Oncorus could file for bankruptcy as most employees laid off; down 43%

April 19, 2024 | Altimetry (Ad)

I’m officially sounding the alarm.

June 1, 2023 | finance.yahoo.com

Oncorus Announces Workforce Reduction Plan

May 23, 2023 | finanznachrichten.de

Oncorus, Inc.: Oncorus Reports First Quarter 2023 Financial Results and Provides Business Updates

May 22, 2023 | msn.com

Recap: Oncorus Q1 Earnings

May 22, 2023 | finance.yahoo.com

Oncorus Reports First Quarter 2023 Financial Results and Provides Business Updates

March 24, 2023 | finanznachrichten.de

Oncorus, Inc.: Oncorus Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Updates

March 24, 2023 | finance.yahoo.com

Oncorus Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Updates

March 15, 2023 | bizjournals.com

For some biotechs moving on from SVB, not all traditional banks are an option

March 11, 2023 | markets.businessinsider.com

Roku Has 26% Of Cash With SVB Financial, Deposit Recovery Uncertain — 27 Other Companies With Ties To Collapsed Bank

January 4, 2023 | finance.yahoo.com

Oncorus Announces Research Collaboration with Daewoong Pharmaceutical for the Development of Lipid Nanoparticle Formulations for mRNA Drug Candidates

November 30, 2022 | marketwatch.com

Oncorus Shares Plumb New Depths on Job Cuts, Portfolio Reshaping >ONCR

November 30, 2022 | finance.yahoo.com

Oncorus Announces Portfolio Reprioritization to Focus on IV-Administered, Self-Amplifying RNA Medicines for Patients with Cancer

November 23, 2022 | finance.yahoo.com

Oncorus to Participate in Upcoming Investor Conferences

November 18, 2022 | finance.yahoo.com

Oncorus Presents Preclinical Data Supporting ONCR-719, an armed HSV-1 Vector engineered to use the Epidermal Growth Factor Receptor (EGFR/EGFRvIII) for viral entry in Glioblastoma, at the 2022 Society for Neuro-Oncology Annual Meeting

November 7, 2022 | finance.yahoo.com

Oncorus, Inc. (ONCR) Moves to Buy: Rationale Behind the Upgrade

November 2, 2022 | msn.com

Recap: Oncorus Q3 Earnings

October 8, 2022 | fool.com

Oncorus, Inc. (NASDAQ: ONCR)

October 7, 2022 | finance.yahoo.com

Oncorus Announces Publication in Nature Communications Highlighting the Development of its Intravenously Administered Synthetic vRNA/LNP Platform for the Treatment of Cancer

October 5, 2022 | theglobeandmail.com

Oncorus: Top 10 Undervalued Healthcare Stocks on NAS (ONCR)

See More Headlines

Receive ONCR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Oncorus and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 5/22/2023
Today: 4/19/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Current Symbol: NASDAQ:ONCR
CUSIP: N/A
CIK: 1671818
Web: www.oncorus.com
Phone: 339-240-3330
Fax: N/A
Employees: 64
Year Founded: N/A

Profitability

EPS (Most Recent Fiscal Year): N/A
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: N/A
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: N/A
Return on Assets: N/A

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: N/A
Quick Ratio: N/A

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $2.33 per share
Price / Book: 0.05

Miscellaneous

Outstanding Shares: 26,090,000
Free Float: 21,633,000
Market Cap: $3.29 million
Optionable: Optionable
Beta: 3.60

10 "Recession Proof" Stocks That Will Thrive in Any Market

Which stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.

Get This Free Report

Key Executives

Mr. Craig R. Jalbert CIRA (Age 61)
CEO, President, CFO, Treasurer, Secretary & Director
Chris German
Controller

Key Competitors

View All Competitors

ONCR Stock Analysis - Frequently Asked Questions

How were Oncorus' earnings last quarter?: Oncorus, Inc. (NASDAQ:ONCR) announced its earnings results on Monday, May, 22nd. The company reported ($1.18) earnings per share for the quarter, missing the consensus estimate of ($0.70) by $0.48.
What other stocks do shareholders of Oncorus own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Oncorus investors own include Cronos Group (CRON), Deere & Company (DE), GrowGeneration (GRWG), Immunomedics (IMMU), Teck Resources (TECK), Abbott Laboratories (ABT), Ability (ABIL), AbbVie (ABBV), Atlas Air Worldwide (AAWW).
When did Oncorus IPO?: Oncorus (ONCR) raised $87 million in an IPO on Friday, October 2nd 2020. The company issued 5,800,000 shares at $14.00-$16.00 per share. Jefferies, Evercore ISI and Piper Sandler acted as the underwriters for the IPO.

This page (NASDAQ:ONCR) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Oncorus (ONCR) Stock Price, News & Analysis

About Oncorus Stock (NASDAQ:ONCR)

ONCR Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

ONCR Stock Analysis - Frequently Asked Questions

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info